Evicenter
P&T meetings

Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Regulatory submission
BLA approved July 2026
Last updated
50 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Anti-VEGF monoclonal antibodies and antibody fragments

2 evidence topics · 1 source

Ranibizumab mechanism of action

“Ranibizumab binds to the receptor binding site of active forms of VEGF-A” (opens the source at this quote in a new tab)

Ranibizumab indication and dosing for wet AMD

“LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD)” (opens the source at this quote in a new tab)

“LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).” (opens the source at this quote in a new tab)